10x Genomics (TXG) Receivables - Net (2018 - 2026)

10x Genomics (TXG) has 9 years of Receivables - Net data on file, last reported at $39.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 25.72% year-over-year to $39.0 million; the trailing twelve-month figure through Mar 2026 stood at $39.0 million (down 25.72% YoY), and the FY2025 full-year result was $47.0 million, down 46.49% from the prior year.
• Receivables - Net retreated to $39.0 million in Q1 2026, from $47.0 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $114.8 million in Q4 2023 to a low of $39.0 million in Q1 2026.
• A 5-year average of $77.1 million and a median of $83.5 million in 2024 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net surged 33.3% in 2022 and sank 47.59% in 2025, its largest moves.
• Tracing TXG's Receivables - Net over 5 years: stood at $104.2 million in 2022, then grew by 10.19% to $114.8 million in 2023, then dropped by 23.49% to $87.9 million in 2024, then slumped by 46.49% to $47.0 million in 2025, then declined by 16.98% to $39.0 million in 2026.
• Business Quant data shows TXG's Receivables - Net at $39.0 million in Q1 2026, $47.0 million in Q4 2025, and $43.8 million in Q3 2025.